A 24-Week Randomized, Doubleblinded Multicenter Active Controlled (Pioglitazone) Study to Evaluate the Efficacy Safety and Tolerability of Tesaglitzar Therapy

Grants and Contracts Details

StatusFinished
Effective start/end date9/27/04 → 3/31/06

Funding

  • AstraZeneca Pharmaceuticals AB: $54,030.00